Posted on January 1st, 2010 by
T.) Treatment Options for Patients with Recurrent Disease after HIPEC, HRA – Panel Discussion Presenters: H. Richard Alexander, MD, University of Maryland School of Medicine & Claire F. Verschraegen, MD, University of New Mexico. At the University of New Mexico Cancer Research and Treatment Center, [Dr. Verschraegen] built the Clinical Trial Office and served as the medical director of the New Mexico Cancer Care Alliance, which promotes clinical trials in the community. She is now the Director of the Translational Therapeutics program and continues her clinical research activities in drug development for gynecological cancers and rare malignancies. Link
You must be logged-in to the site to post a comment.